Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical interaction study on concurrent use of Samryungbaekchulsan and otilonium bromide for irritable bowel syndrome: safety and effectiveness
KCT0001621Phase 4Recruiting
- Sponsor
- Korea Institute of Oriental Medicine
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of otilonium in irritable bowel syndrome (IBS), sponsored by Korea Institute of Oriental Medicine. Started Mar 2016; status: recruiting.
02
Drugs
otilonium
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on KCT0001621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001621.